PuSH - Publication Server of Helmholtz Zentrum München

Journal browsing

78 Records found.
Zum Exportieren der Ergebnisse bitte einloggen.
Lay all publications on this page into basket
Correa-Gallegos, D. ; Machens, H.G.* & Rinkevich, Y.: States and fates of skin fibroblasts revealed through chromatin accessibility. J. Invest. Dermatol. 142, 1767-1770 (2022)
Speth, P.* et al.: Immunocompromised patients with therapy-refractory chronic skin diseases show reactivation of latent EBV and CMV infection. J. Invest. Dermatol. 142, 549-558.e6 (2022)
Seiringer, P. ; Garzorz-Stark, N.* & Eyerich, K.*: T-cell‒mediated autoimmunity: Mechanisms and future directions. J. Invest. Dermatol. 142, 804-810 (2021)
Thomas, J. et al.: CD23 levels on B cells determine long-term therapeutic response in patients with atopic eczema treated with selective IgE immune apheresis. J. Invest. Dermatol. 141, 681-685.e6 (2021)
Chuah, S.Y.* et al.: Volumetric multispectral optoacoustic tomography for 3-dimensional reconstruction of skin tumors: A further evaluation with histopathologic correlation. J. Invest. Dermatol. 139, 481-485 (2019)
Eyerich, K.* & Eyerich, S.: Immune response patterns in chronic inflammatory skin diseases a basis of targeted therapy. J. Invest. Dermatol. 138, S16-S16 (2018)
Heppt, M.V.* et al.: MSX1-induced neural crest-like reprogramming promotes melanoma progression. J. Invest. Dermatol. 138, 141-149 (2018)
Hiller, J. et al.: STAT1 gain-of-function and dominant negative STAT3 mutations impair IL-17 and IL-22 immunity associated with CMC. J. Invest. Dermatol. 138, 711-714 (2018)
Jargosch, M.* et al.: Necroptosis as special type of cell death in inflammatory skin diseases. J. Invest. Dermatol. 138, S116-S116 (2018)
Lauffer, F.* et al.: Type I immune response induces keratinocyte necroptosis and is associated with interface dermatitis. J. Invest. Dermatol. 138, 1785-1794 (2018)
Schmidt, M.O.* et al.: The role of Fibroblast growth factor binding protein 1 in skin carcinogenesis and inflammation. J. Invest. Dermatol. 138, 179-188 (2018)
Buters, J.T.M. & Biedermann, T.*: Chromium(VI) contact dermatitis: Getting closer to understanding the underlying mechanisms of toxicity and sensitization! J. Invest. Dermatol. 137, 274-277 (2017)
Fuertes, E.* ; Flohr, C.* ; Silverberg, J.I.* ; Standl, M. & Strachan, D.P.*: Global associations between UVR exposure and current eczema prevalence in children from ISAAC Phase Three. J. Invest. Dermatol. 137, 1248-1256 (2017)
Garzorz-Stark, N.* et al.: TLR7/8 agonists stimulate plasmacytoid dendritic cells to initiate a Th17-deviated acute contact dermatitis in humans. J. Invest. Dermatol. 137, S275-S275 (2017)
Guttman-Yassky, E.* et al.: A pathogenic role for Th22/IL-22 in atopic dermatitis is established by a placebo-controlled trial with an anti IL-22/ILV-094 mAb. J. Invest. Dermatol. 137, S53-S53 (2017)
Hermann, H.* et al.: miR-146b probably assists miRNA-146a in the suppression of keratinocyte proliferation and inflammatory responses in psoriasis. J. Invest. Dermatol. 137, 1945-1954 (2017)
Kong, H.H.* et al.: Performing skin microbiome research: A method to the madness. J. Invest. Dermatol. 137, 561-568 (2017)
Laemmermann, I.* et al.: Blocking negative effects of senescence in human skin fibroblasts with a plant extract. J. Invest. Dermatol. 137, S311-S311 (2017)
Lauffer, F.* et al.: Interface Dermatitis is characterized by a type I immune response and an epidermal reaction to IFN-gamma and TNF-alpha. J. Invest. Dermatol. 137, S254-S254 (2017)
Standl, M. et al.: Association of atopic dermatitis with cardiovascular risk factors and diseases. J. Invest. Dermatol. 137, 1074-1081 (2017)